Eli Lilly hits another Alzheimer ' s drug hurdle. But the main reason to own the stock remains solidly intact

Eli Lilly 's experimental Alzheimer's treatment hit another hurdle with U.S. drug regulators. It pushed out the timeline for potential approval but did not rattle our investment thesis in the company. The Food and Drug Administration plans to call a meeting of a key advisory panel to review trial…#elililly #indianapolis #lilly #fda #jimcramer #glp1 #zepbound #biogen #leqembi #eisaileqembi
Source: Reuters: Health - Category: Consumer Health News Source Type: news